- Home
- ERNA vs HSCS Comparison
ERNA vs HSCS Comparison
Compare ERNA & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ERNA | HSCS |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | United States | United States |
| Employees | N/A | 12 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7M | 8.2M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ERNA | HSCS |
|---|---|---|
| Price | $0.24 | $2.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.20 |
| AVG Volume (30 Days) | ★ 1.2M | 6.7K |
| Earning Date | 03-16-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.29 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $582,000.00 | N/A |
| Revenue This Year | N/A | $1,072.41 |
| Revenue Next Year | N/A | $2,700.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.15 | $2.01 |
| 52 Week High | $3.00 | $6.47 |
Technical Indicators
Market Signals| Indicator | ERNA | HSCS |
|---|---|---|
| Relative Strength Index (RSI) | 25.45 | 33.60 |
| Support Level | $0.16 | $2.16 |
| Resistance Level | $0.35 | $3.28 |
| Average True Range (ATR) | 0.03 | 0.13 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 11.39 | 12.16 |
Price Performance
Historical ComparisonAbout ERNA Eterna Therapeutics Inc.
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.